Results 61 to 70 of about 798 (134)

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. [PDF]

Signal Transduct Target Ther
Wu J, Li X, Gu C, Hua L, Liu R, Li J, Qiu M, Guo J, Dong H, Ji Z, Xie L, Zhu S, Zhang X, Chen P, Jiang S, Sun Z, Xu D, Chen H, Shi B, Wang Y, Pu J, Perabo F, Chen Y, Ye D.   +23 more
europepmc   +1 more source

Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Rajendran R, Lap CJ, Madapoosi S, Heiraty A, Estephan F, Hahn W, Poudel A, Nava VE, Subrahmanyam R, Jain M.   +9 more
europepmc   +1 more source

The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer. [PDF]

Asian J Androl
Wang Q, Zhang M, Zhu QY, Zeng H, Dai JD, Huang K, Wan SC, Shi YF, Zhang XM, Zeng H, Shen PF.   +10 more
europepmc   +1 more source

Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial. [PDF]

Clin Transl Med
Liu Z, Chen B, Dai T, Jiang S, Luo H, Liao H, Yu D, Chen Z, Zhang D, Li Z, Zhang Z, Bai H, Liu F, Lin J, Wang Y, Feng P, Wei Q.   +16 more
europepmc   +1 more source

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients. [PDF]

Int J Mol Sci
Posocco B, Pasin D, De Cesaro N, Pivetta A, Gagno S, Canil G, Cecchin E, Cecchin R, Speziani S, Dri A, Bortolus G, Spina M, Santarossa S, Puglisi F, Fratino L, Cecchin E.   +15 more
europepmc   +1 more source

Effects of doxazosin as adjuvant to abiraterone on viability and apoptosis of metastatic castration-resistant prostate cells cancer (mCRPC) PC3. [PDF]

Narra J
Pratama PK, Rahman ZA, Hidayatullah F, Laksita TB, Hakim L.   +4 more
europepmc   +1 more source

Site-Specific Abiraterone Protein-Drug Conjugates via Hedgehog Autoprocessing. [PDF]

ACS Appl Mater Interfaces
Gulzar A, Maryam L, Valappil S, Thanthrige V, de Jong E, Guzman M, Hossain MS, Acharya A, Mozhdehi D.   +8 more
europepmc   +1 more source

Casticin inhibits AKR1C3 and enhances abiraterone efficacy in castration-resistant prostate cancer. [PDF]

J Nat Med
Piska K, Zubek M, Bucki A, Świtalska M, Koczurkiewicz-Adamczyk P, Władyka B, Kołaczkowski M, Pękala E.   +7 more
europepmc   +1 more source

Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study. [PDF]

Prostate Cancer Prostatic Dis
Chan JSK, Lee YHA, Leung CH, Leung DKW, Dee EC, Ng K, Tse G, Ng CF.   +7 more
europepmc   +1 more source

Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide. [PDF]

Cancer Med
Brown JT, Nazha B, Ferreira AC, Armeson K, Hill EG, Ogretmen B, Mehrotra S, Brisendine A, Magrath G, Plasse TF, Gourdin TS, Kucuk O, Lilly M.   +12 more
europepmc   +1 more source